WAVE Life Sciences Ltd (NAS:WVE)

$ 5.74 0.22 (3.99%) Market Cap: 716.00 Mil Enterprise Value: 590.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

Q4 2023 WAVE Life Sciences Ltd Earnings Call Transcript
Mar 06, 2024

$6.29 (+31.32%)

Earnings
WAVE Life Sciences Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 WAVE Life Sciences Ltd Earnings Call Transcript
Nov 09, 2023

$5.21 (-9.55%)

Earnings
WAVE Life Sciences Ltd R&D Day Transcript
Sep 28, 2023
Q2 2023 WAVE Life Sciences Ltd Earnings Call Transcript
Aug 03, 2023

$5.06 (+15.79%)

Earnings
WAVE Life Sciences Ltd FOCUS-C9 Clinical Trial Results Conference Call Transcript
May 23, 2023
Q1 2023 WAVE Life Sciences Ltd Earnings Call Transcript
May 03, 2023

$3.75 (+1.90%)

Earnings
Q4 2022 WAVE Life Sciences Ltd Earnings Call Transcript
Mar 22, 2023

$3.8 (-10.38%)

Earnings
WAVE Life Sciences Ltd WVE-N531 Clinical Trial Update Call Transcript
Dec 19, 2022
WAVE Life Sciences Ltd Business Update Transcript
Dec 13, 2022
Q3 2022 WAVE Life Sciences Ltd Earnings Call Transcript
Nov 10, 2022

$4.17 (+5.84%)

Earnings
WAVE Life Sciences Ltd Investor Event Transcript
Sep 28, 2022
WAVE Life Sciences Ltd SELECT-HD Clinical Trial Update Transcript
Sep 20, 2022
Q2 2022 WAVE Life Sciences Ltd Earnings Call Transcript
Aug 11, 2022

$2.98 (+16.86%)

Earnings
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022
Q1 2022 WAVE Life Sciences Ltd Earnings Call Transcript
May 12, 2022

$1.29 (-12.24%)

Earnings
WAVE Life Sciences Ltd Genetic Medicines and Cell Therapy Manufacturing Summit Transcript
Apr 26, 2022
WAVE Life Sciences Ltd to Discuss the FOCUS-C9 Clinical Trial Update Investor Call Transcript
Apr 04, 2022
WAVE Life Sciences Ltd at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Q4 2021 WAVE Life Sciences Ltd Earnings Call Transcript
Mar 03, 2022

$2.39 (-2.85%)

Earnings
Q3 2021 WAVE Life Sciences Ltd Earnings Call Transcript
Nov 10, 2021

$4.69 (+0.43%)

Earnings
WAVE Life Sciences Ltd Analyst And Investor Research Corporate Call Transcript
Sep 28, 2021
Q2 2021 WAVE Life Sciences Ltd Earnings Call Transcript
Aug 05, 2021

$6.03 (+8.65%)

Earnings
Q1 2021 WAVE Life Sciences Ltd Earnings Call Transcript
May 13, 2021

$5.86 (-4.25%)

Earnings
WAVE Life Sciences Ltd PRECISION-HD Trial Results and Business Update Call Transcript
Mar 29, 2021
Q4 2020 WAVE Life Sciences Ltd Earnings Call Transcript
Mar 04, 2021

$9.34 (-8.79%)

Earnings
WAVE Life Sciences Ltd at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 25, 2021
WAVE Life Sciences Ltd at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2020
Q3 2020 WAVE Life Sciences Ltd Earnings Call Transcript
Nov 09, 2020

$7.48 (+3.60%)

Earnings
Wave Life Sciences Ltd. - Shareholder/Analyst Call Transcript
Aug 25, 2020
Q2 2020 WAVE Life Sciences Ltd Earnings Call Transcript
Aug 10, 2020

$9.43 (+3.06%)

Earnings
Q1 2020 WAVE Life Sciences Ltd Earnings Call Transcript
May 11, 2020

$10.11 (+26.85%)

Earnings
Q4 2019 WAVE Life Sciences Ltd Earnings Call Transcript
Mar 02, 2020

$7.93 (-6.04%)

Earnings
WAVE Life Sciences Ltd Corporate Call Transcript
Dec 30, 2019
Wave Life Sciences Ltd Suvodirsen Update Conference Call Transcript
Dec 16, 2019
WAVE Life Sciences Ltd to Host Analyst and Investor Research Day Transcript
Oct 07, 2019

WAVE Life Sciences Ltd WVE-N531 Clinical Trial Update Call Transcript

Dec 19, 2022 / 01:30PM GMT

Release Date Price: $5.23 (+0.77%)

Transcript

Operator

Good morning, and welcome to the Wave Life Sciences WVE-N531 proof-of-concept clinical trial conference call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, Investor Relations at Wave Life Sciences. Please go ahead.

Unidentified Company Representative

Thank you, operator. Good morning, and thank you for joining us today. I will be covering for Kate Rausch, while she's out on maternity leave. This morning, we issued a new release, providing an update on the initial cohort of our Phase Ib/IIa proof-of-concept clinical trial evaluating N531 as a potential treatment for Duchenne muscular dystrophy. A slide presentation to accompany this webcast is available at the Investor Relations section of our website at www.wavelifesciences.com. A replay will also be available on the website following today's call.

Before we begin, I would like to remind you that discussions during this conference call will include

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.